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Abstract
Background: Immunomagnetic enrichment followed by RT-PCR (immunobead RT-PCR) is an
efficient methodology to identify disseminated carcinoma cells in the blood and bone marrow. The
RT-PCR assays must be both specific for the tumor cells and sufficiently sensitive to enable
detection of single tumor cells. We have developed a method to test RT-PCR assays for any cancer.
This has been investigated using a panel of RT-PCR markers suitable for the detection of breast
cancer cells.
Methods: In the assay, a single cell line-derived tumor cell is added to 100 peripheral blood
mononuclear cells (PBMNCs) after which mRNA is isolated and reverse transcribed for RT-PCR
analysis. PBMNCs without added tumor cells are used as specificity controls. The previously
studied markers epidermal growth factor receptor (EGFR), mammaglobin 1 (MGB1), epithelial cell
adhesion molecule (EpCAM/TACSTD1), mucin 1 (MUC1), carcinoembryonic antigen (CEA) were
tested. Two new epithelial-specific markers ELF3 and EphB4 were also tested.
Results: MUC1 was unsuitable as strong amplification was detected in 100 cell PBMNC controls.
Expression of ELF3, EphB4, EpCAM, EGFR, CEA and MGB1 was found to be both specific for the
tumor cell, as demonstrated by the absence of a signal in most 100 cell PBMNC controls, and
sensitive enough to detect a single tumor cell in 100 PBMNCs using a single round of RT-PCR.
Conclusions: ELF3, EphB4, EpCAM, EGFR, CEA and MGB1 are appropriate RT-PCR markers for
use in a marker panel to detect disseminated breast cancer cells after immunomagnetic enrichment.
Background
Reverse transcriptase-polymerase chain reaction (RT-PCR)
assays have been developed for the detection of dissemi-
nated carcinoma cells by targeting epithelial or tumor spe-
cific mRNA in bone marrow, peripheral blood, or lymph
nodes (reviewed in [1]). However limitations may arise
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from deficient expression in circulating tumor cells or low
level illegitimate expression in haematopoietic cells, par-
ticularly if a nested PCR approach is used [2–5].
We developed an immunobead-based technique for the
enrichment of epithelial cells to increase the signal to
noise ratio for PCR based protocols [6]. This was subse-
quently adapted to RT-PCR methodology [7]. We have
shown immunobead RT-PCR is of sufficient sensitivity to
identify 1 tumor epithelial cell in a background of 106
blood cells [7,8]. A recent study compared immunobead
RT-PCR with regular RT-PCR using CEA as the marker for
colon cancer cells spiked into normal blood samples and
confirmed that the immunobead RT-PCR method is more
sensitive and specific than the regular RT-PCR method [9].
Up to 100 peripheral blood leukocytes (PBLs) may be
concurrently isolated with the tumor cells during the im-
munobead method [10]. We previously had similar levels
of PBL contamination. Now that we carry out incubations
at 4°C and take off the cell pellets from the magnets for
washing, considerably fewer than 10 cells are isolated
(unpublished observations). It is nevertheless important
to assess whether this small number of cells can lead to
false positives due to illegitimate expression.
In this paper, we introduce a new strategy for the testing
of RT-PCR assays using a method in which a single tumor
cell is mixed with 100 PBMNCs prior to RT-PCR analysis.
100 PBMNCs without added tumor cells are used as spe-
cificity controls. This method has allowed the identifica-
tion of a panel of RT-PCR markers of sufficient sensitivity
and specificity for immunobead RT-PCR. This study in-
cludes an assessment of 2 previously untested markers
ELF3 (also known as ESX) [11] and EphB4 [12], as well as
the previously studied markers mucin 1 (MUC1), carci-
noembryonic antigen (CEA), epidermal growth factor re-
ceptor (EGFR), epithelial cell adhesion molecule
(EpCAM) and mammaglobin 1 (MGB1) markers.
Whether a RT-PCR is useful depends not only on the
marker used but also on the assay conditions for that
marker. A useful marker will be both sensitive enough to
enable detection of a single tumor cell and specific
enough to not be amplified from PBLs. However, as im-
munomagnetic cell isolates have very low contamination
by PBLs, it is desirable to check the possibility of illegiti-
mate expression in the very low number of PBLs that are
retained after an immunobead harvest. To test both spe-
cificity and sensitivity of our chosen markers, we devel-
oped an assay in which a single tumor cell is deposited
into a microcentrifuge tube containing 100 normal PBM-
NCs. 100 PBMNCs were chosen as we believe that this
number covers the maximum amount of PBMNC con-
tamination that we or others are likely to encounter.
Methods
Patient samples
Peripheral blood was collected from patients with poly-
cythemia vera who presented for treatment at The Queen
Elizabeth Hospital, Adelaide, Australia. Informed consent
was obtained in all cases and ethics approval was ob-
tained from The Queen Elizabeth Hospital Ethics of Hu-
man Research Committee. Mononuclear cells were
collected by centrifugation through a Ficoll gradient,
washed with phosphate-buffered saline (PBS) and count-
ed using a haemocytometer. In the course of this investi-
gation, PBMNCs from eight different patients were used.
Cell lines
The breast cancer cell lines MDA-MB-453, T47-D, MDA-
MB-468, MCF-7, were cultured in DMEM, pH 7.4 (Invit-
rogen, Carlsbad, CA) supplemented with 100 U/ml peni-
cillin, 100 µg/ml streptomycin, 160 µg/ml L-glutamine
and 10% heat-inactivated fetal bovine serum (JRH Bio-
sciences, Lenexa, KS) in 75 cm2 vented tissue culture flasks
at 37°C in a 5% CO2 environment. Log phase cells were
collected at less than 90% confluency by trypsin digestion
and centrifugation for 5 min at 1000 rpm, resuspended in
phosphate buffered saline (PBS) and counted using a
haemocytometer. The cell lines were purchased from the
American Type Culture Collection (ATCC, Rockville,
MD).
Single Cell RT-PCR
A dilute suspension of a cell line was prepared in calcium
and magnesium free Dulbecco's PBS. Single cells were vis-
ualised using an inverted phase microscope and selected
by using a micropipette to draw up the cell in a 1 µl vol-
ume. The cell was deposited into a 0.5 ml microcentrifuge
tube containing 100 peripheral blood mononuclear cells
in 1 µl of calcium and magnesium free Dulbecco's PBS. Al-
iquots that contained 100 mononuclear cells only were
included as controls for the specificity of the RT-PCR. The
cell mixture was lysed in a 15 µl volume of solution con-
taining 0.3 % v/v Nonidet P-40 detergent (Sigma), 500 ng
random hexamers (Pharmacia, Uppsala, Sweden), 20 U of
RNasin (Promega, Madison, WI) and 10 mM DTT. Fol-
lowing 70°C denaturation for 3 minutes, reverse tran-
scription was initiated by the addition of 5×  First Strand
Buffer, 200 U of Superscript II (Invitrogen), 0.5 mM of
each deoxynucleotide triphosphate (Roche, Mannheim,
Germany), with Ultra-pure water (Fisher Biotech, Perth,
Australia) to a final volume of 30 µl. The reaction was in-
cubated at 42°C for 50 minutes, and then the reverse tran-
scriptase was inactivated at 70°C for 10 minutes.
After reverse transcription, 4 µl of cDNA was used as the
template in a single round of PCR amplification with 200
nM of each gene specific primer pair (Table 1), 1 U of Hot
Star Taq (Qiagen, Valencia, CA), 2.5 mM MgCl2, and 200BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/14
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µM of each deoxynucleotide triphosphate, in the supplied
PCR buffer. Cycling conditions included an initial dena-
turation step at 95°C for 15 minutes, then 1 minute at
each of 94°C, 66–68°C and 72°C for 45–55 cycles and a
final extension of 7 minutes at 72°C. Amplification prod-
ucts were visualised by ethidium bromide staining follow-
ing separation by electrophoresis through agarose gels. In
each case an RT negative control, made up of the compo-
nents of the RT reaction mixture with or without lysis mix,
and without the addition of RNA, was used as the tem-
plate in the PCR reaction (no cDNA made and therefore
no amplification expected). The PCR negative control
contains the reagents of the PCR reaction but lacks tem-
plate. Cell line cDNA was included as a positive control
for the PCR reaction. Genomic DNA (100 ng) was used to
confirm that a product of equal size to the cDNA product
would not be amplified from the DNA in the cell lysate.
Results
Expression of markers in breast cancer cell lines
The expression of each of the RT-PCR markers was as-
sessed for its suitability as a breast cancer marker. RNA
was extracted from seven breast cancer cell lines, reverse
transcribed into cDNA then amplified using primers spe-
cific for the different markers (Table 1). Transcripts corre-
sponding to EpCAM were amplified from all of the cell
lines tested (Fig. 1., panel 1). This validates the use of an-
tibodies that recognise epitopes of this protein as the im-
munobead label for magnetic isolation of the breast
carcinoma cells [6] and confirms earlier results which
showed uniform bright fluorescence in breast cancer cell
lines and biopsies stained with one of these antibodies,
Ber-Ep4 [7].
ELF3, EphB4 and MUC1 were amplified in all cell lines at
consistently high levels (Fig. 1, panels 2, 3 and 4). EGFR
expression was also easily detectable (Fig. 1, panel 5) even
though several reports have suggested it is expressed at
low levels in MCF-7 and T47-D and is not expressed in
MDA-MB-453 [13,14]. MGB1 transcripts were amplified
from all cell lines except for MCF-7 (Fig. 1, panel 2) and
CEA was amplified from all cell lines except PMC42 (Fig.
1 panel 6).
Expression of markers in single tumor cell/100 PBMNC 
mixes
Tubes that contained 100 PBMNCs and one tumor cell
were used to determine the sensitivity of each RT-PCR
marker. Most of the sensitivity tests were performed using
MDA-MB-453 cells but four different breast cancer cell
lines have been included in this part of the study, two that
are ER negative (MDA-MB-453, and MDA-MB-468) and
two that are ER positive (MCF-7 and T47-D).
Analysing the samples to which a single breast cancer cell
had been added to 100 PBMNC showed that we can detect
the tumor cell most often with ELF3 (40/43 – 93%) and
EpCAM (36/40 – 89%) (Figures 2 and 3, tables 2 and 3).
EphB4 specific amplification detected 31/40 (77.5%),
MUC1 10/20 (67%), CEA 9/20 (45%), EGFR 19/43
(44%) and MGB1 9/35 (26%).
Table 1: Primer sequences (sense (s) and anti-sense (as)), melting temperatures (Tm), annealing temperature and expected product 
size in nucleotides (nt) for each of the seven selected marker genes.
Name Sequence 5' – 3' Tm Annealing Size
MUC1 s ACCAAGACTGATGCCAGTAGCACT 65°C
MUC1 as ACCGTTACCTGCAGAAACCTTCT 63°C6 8 °C1 1 5  n t
ESX s CTCGGAGCTCCCACTCCTCAGA 68°C
ESX as GCTCTTCTTGCCCTCGAGACAGT 67°C6 8 °C1 8 8  n t
CEA s GGTTGGGGTTGCTCTGATATAGCAGC 70°C
CEA as GCTGTTGCAAATGCTTTAAGGAAGAAGC 67°C6 6 °C9 7  n t
EPHB4 s CCCCAGGGAAGAAGGAGAGCTG 68°C
EPHB4 as GCCCACGAGCTGGATGACTGTG 68°C6 8 °C2 5 0  n t
EGFR s TGTGAGGTGGTCCTTGGGAATTTGG 67°C
EGFR as TGCTGACTATGTCCCGCCACTGGA 69°C6 6 °C3 3 9  n t
EpCAM s GGACCTGACAGTAAATGGGGAAC 65°C
EpCAM as CTCTTCTTTCTGGAAATAACCAGCAC 65°C6 8 °C1 8 6  n t
MGB1 s CGGATGAAACTCTGAGCAATGTTGAG 66°C
MGB1 as CTGCAGTTCTGTGAGCCAAAGGTC 67°C6 8 °C1 1 0  n t
Primer sequences (sense (s) and anti-sense (as)), melting temperatures (Tm), annealing temperature and expected product size in nucleotides (nt) 
for each of the seven selected marker genes. The TM (Salt adjusted) was calculated using the web-based Oligonucleotide Properties calculators  
[http://www.basic.nwu.edu/biotools/oligocalc.html.] BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/14
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Expression of markers in a background of 100 PBMNCs
Tubes that contained 100 PBMNCs only were included to
determine specificity (Table 2). After combining the data
obtained from several different experiments and several
different normal individuals in reactions using the appro-
priate number of amplification cycles, we found no ex-
pression of EGFR (0/27), MGB1 (0/24), EphB4(0/21),
EpCAM (0/21) or CEA (0/18), (Figures 2 and 3, Table 2).
Only ELF3 and MUC1 gave positive bands.
These results were for 45 cycles of amplification except for
CEA which was run for 55 cycles. We also examined ELF3,
EphB4 and MUC1 at 55 cycles in a small number of exper-
iments. We amplified transcripts that corresponded to
ELF3 (1/6), EphB4 (3/12) and MUC1 (3/12) in some of
the PBMNC control tubes. The ELF3 and EphB4 bands
were visible following ethidium bromide staining but
were less intense than the band amplified after the addi-
tion of a single tumor cell and in no cases were all three of
the PBMNC controls positive in the same experiment.
We assume that the ELF3 band is a result of amplification
of illegitimate transcripts. This band was eliminated when
only 35 cycles of amplification (0/15) were performed but
because only a small amount of product was amplified af-
ter 45 or 55 cycles in these controls we could distinguish
samples that contained tumor cells and those that did not
through comparison of the intensity of bands. Analysing
the samples to which a single breast cancer cell had been
added to 100 PBMNC showed that we could still detect
the tumor cell most often with ELF3 (15/16 – 94%). Tests
using single tumour cells in a 100 PBMNC background
detected 15/16 (94%) of tumour cells after 35 cycles. Un-
like ELF3, the MUC1 PBMNC band was of comparable in-
tensity to those achieved after tumor cell addition making
Figure 1
Expression of seven RT-PCR markers in a panel of seven
breast cancer cell lines. Each marker is shown in a separate
panel and the size of the amplified product is indicated in
base pairs (bp) M indicates the pUC19/HpaII marker, -ve
indicates the RT-PCR negative control. Weak genomic or
primer dimer bands are seen for some RT-PCRs.
Figure 2
Expression of seven RT-PCR markers in 5 separate single
MDA-MB-453 cells lysed with 100 normal PBMNC. Lane M –
pUC19/HpaII molecular weight marker. The following 3 lanes
are amplifications from 100 PBMNC only. The following 5
lanes are amplifications from one MDA-MB-453 cell in 100
PBMNC, Lane C is the cDNA positive control, Lane G is the
genomic DNA control (G), Lane R is the RT – negative con-
trol; Lanes labelled N are the PCR negative controls.
Genomic bands can be seen for many ELF3 amplifications.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/14
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it impossible to distinguish samples that contain tumor
cells from those that don't (Figure 2).
Discussion
The development of optimized methods for detecting tu-
mor cells in the peripheral blood and bone marrow of
cancer patients may enhance our ability to identify those
patients in need of further therapy. Nested RT-PCR of PB-
MNCs has been the most common method to detect epi-
thelial – specific markers. Due to the high level of
sensitivity of nested RT-PCR, even low levels of illegiti-
mate transcription in PBMNCs can cause false-positive re-
sults [2–5]. Nested RT-PCR is also more time consuming
and stringent procedures need to be observed in order to
minimise the risk of false positives due to PCR product
cross contamination. It is thus desirable that the RT-PCR
is performed in a single round to avoid potential contam-
ination problems.
The use of immunobead enrichment prior to reverse tran-
scription has allowed the use of a single round of PCR am-
plification to screen a whole blood sample. Our original
methodology used blotting and detection with an oligo-
nucleotide to increase sensitivity [7] but this is no longer
necessary with the more efficient RT-PCR assays presented
here, in particular because of the use of a hot start Taq
polymerase. To improve RT-PCR detection further, the
identification of epithelial or carcinoma cell specific
markers that are expressed at a sufficient level to enable
detection of a single cell after only one round of non-nest-
ed PCR are needed. For this reason, we have used single
tumor cells in a background of 100 PBMNCs to screen sev-
en different RT-PCR assays in order to identify the best
ones for inclusion in a panel for the immunobead RT-PCR
based detection of circulating tumor cells.
We used breast cancer cell lines as the source of tumor
cells. Whereas breast cancer cell lines may have different
levels of expression of markers compared to disseminated
breast cancer cells, cells from different individuals, and
even within an individual, are likely to display considera-
ble heterogeneity. We sought to overcome this difficulty
by using a number of cell lines. The use of cell lines has
the great advantage of providing reproducible controls to
test the sensitivity of the RT-PCR assays during studies of
patient material.
The immunobead enrichment step relies on the expres-
sion of an epithelial cell adhesion molecule (EpCAM)
(current gene symbol, TACTSD1, tumor-associated calci-
um signal transducer 1), which is recognized by an anti-
b o d y  o n  i m m u n o b e a d s .  W e  c o n s i d e r e d  t h i s  t o  b e  a n
appropriate positive control, as any cell that is detected us-
ing the immunobeads should express the EpCAM gene. All
of the breast cancer cell lines expressed the EpCAM gene
and no message was detected in any of 24 aliquots that
contained 100 PBMNC. Tests of the single tumor cell and
100 PBMNC aliquots with EpCAM showed that it was also
expressed to a sufficient level to enable detection of the tu-
mor cell in 31/35 (89%) cases after 45 cycles of PCR am-
plification. We therefore consider EpCAM a useful
addition to a marker panel for the detection of breast tu-
mor cells. It is possible that the sensitivity with this mark-
er can be improved if more PCR cycles are performed.
Mucin 1 (MUC1) is another epithelial glycoprotein ex-
pressed in breast epithelial cells. It is a commonly used if
controversial marker for detection of circulating tumor
cells [5]. Recently, it was reported that that immunomag-
netic separation followed by MUC1-specific real time RT-
PCR allowed the semi-quantitative detection of circulat-
ing mammary cells if amplification above a cycle thresh-
old value of 38 was obtained [15]. Using our assay, MUC1
transcripts were detected in 1/6 100 PBMNC only samples
Figure 3
Expression of seven RT-PCR markers in 5 separate single
MCF-7 cells lysed with 100 normal MNC. Lane M – pUC19/
HpaII molecular weight marker. The following 3 lanes are
amplifications from 100 PBMNC only. The following 5 lanes
are amplifications from one MCF-7 cell in 100 PBMNC, Lane
C is the cDNA positive control, Lane G is the genomic DNA
control (G), Lane R is the RT – negative control; Lanes
labelled N are the PCR negative controls. Genomic bands
can be seen for many ELF3 amplifications,BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/14
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Table 2: Comparison of the expression of the seven selected markers in either 100 PBMNCs only, or after the addition of a single tumor 
cell from one of four different cell lines.
ELF3 EpCam EphB4 MUC1 CEA EGFR MGB1
Cycles 45 45 45 45 55 45 45
100 PBMNC 5/30 0/21 0/21 1/6 0/18 0/27 0/24
453 17/18 5/5 9/10 5/10 0/10 8/18 4/10
468 5/5 5/5 5/5 ND ND 5/5 ND
MCF-7 10/10 8/10 6/10 5/5 9/10 1/5 1/10
T-47D 8/10 13/15 11/15 ND ND 5/15 4/15
TOTAL 40/43 31/35 31/40 10/15 9/20 19/43 9/35
Comparison of the expression of the seven selected markers in either 100 PBMNCs only, or after the addition of a single tumor cell from one of 
four different cell lines (MDA-MB-453, MDA-MB-468, MCF-7 and T47-D) after 45 or 55 rounds (CEA) of PCR amplification. For example EphB4 
was detected in 9 out of 10 single MDA-MB-453 cells added to 100 PBMNC aliquots. ND- test not performed.
Table 3: Profile of gene expression from 10 different experiments each using 5 single tumour cell/100 PBMNC aliquots from four differ-
ent cell lines.
MDA-MB-468 MDA-MB-453 MDA-MB-453 MDA-MB-453
12345123451234512345
ELF3 ++++++++++++++++++++
EphB4 +++++++++++++++++++-
EpCam +++++ ++++++++++
EGFR ++++++- -++-+-+-++- - -
MGB1 ----- ---+-+--+ +
T-47D T-47D T-47D T-47D
12345123451234512345
ELF3 +++++ +++++++-+-
EphB4 +++++-++-++++++++-+-
EpCam +++++++++++-+++++++-
EGFR ------+-------++++- -
MGB1 --------+ +-----+ +---
MCF-7 MCF-7
1234512345
ELF3 ++++++++++
EphB4 -++++-+-+-
EpCam -++-+++-++
EGFR -+---+----
MGB1 ----------
Profile of gene expression from 10 different experiments each using 5 single tumour cell/100 PBMNC aliquots from four different cell lines demon-
strating heterogeneity of gene expression and utility of several markers for accurate detection of the single tumour cell. A "+" indicates that marker 
was detected, a "-" indicates that marker was not detected, and a blank indicates that marker was not done.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/14
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and 10/15 tumor cell samples. Although we did not use
real-time PCR for our assay, the intensity of the positive
bands in the PBMNC only samples was comparable to
that obtained with the tumor cell samples and it was con-
cluded that detection of MUC1 transcripts would result in
too many false positive results to warrant its inclusion in
our panel. Interestingly, during the course of this study it
was reported that a majority of CK(+)/MUC1(+) tumor
cells circulating in the blood of patients with advanced
breast cancer also displayed apoptotic features such as an
"inclusion type" cytokeratin staining pattern and nuclear
condensation with apoptosis-related DNA strand breaks
[16]. It was concluded that the predictive value of such
CK(+)/MUC1(+) positive cells should be considered sep-
arately when analysing tumor cell dissemination, further
supporting our decision not to include MUC1.
Elevated levels of serum carcinoembryonic antigenCEA
are commonly used as a clinical tool in the diagnosis and
monitoring of metastasis but the use of CEA as an immu-
nobead RT-PCR marker [17] has given varying results.
CEA has been considered to show no diagnostic value as
a RT-PCR marker for the detection of micrometastases be-
cause it is expressed in the blood and lymph nodes of pa-
tients without cancer [5]. However, in a comparison of
immunobead RT-PCR and regular RT-PCR amplification,
it was shown that immunobead isolation increases the
specificity of CEA [8]. Using 55 PCR cycles for CEA, we
found amplification in none of the PBMNC only samples
and gained a positive result for 45% of the single tumor
cell samples we tested. Thus, CEA appears to be a very use-
ful marker when immunobead enrichment is performed
prior to RT-PCR.
Epidermal growth factor receptor (EGFR, HER1, ErbB1) is
a tyrosine kinase whose activation plays an important role
in the regulation of cell proliferation, differentiation and
survival with a pivotal role in maintenance and repair of
epithelial tissues. EGFR is overexpressed in 50–70% of hu-
man primary breast, lung, and colon carcinomas [18]. A
study using nested RT-PCR and Southern blotting to de-
tect EGFR transcripts in blood samples from patients with
metastatic colon cancer found that 10.5% of healthy do-
nors were positive which suggests that their assay detected
illegitimate transcription. However, none of the 27 PBM-
NC only aliquots tested in our assay yielded EGFR ampli-
fication products and 19/43 (44%) single tumor cells
were detected. A comparison of the results obtained for
the two ER positive cell lines (6/20) with those obtained
for the two ER negative cell lines (13/23) suggests that ER
status will affect the efficacy of this marker but it remains
a useful marker.
Mammaglobin 1 (MGB1) expression is limited to mamma-
ry epithelium and is often up-regulated in human breast
cancer [20]. The gene has been localised to chromosome
11q13 in a region frequently amplified in breast cancer.
Using nested RT-PCR, it was shown that MGB1 transcripts
are detectable in blood from breast cancer patients [21].
Marchetti et al., (2001) analysed lymph nodes from breast
cancer and normal patients and suggest that MGB1 is a
more sensitive and more specific RT-PCR marker than a
panel of six other markers that included CEA, CK19 and
MUC1[22]. MGB1 transcripts were not detected by us in
any of the PBMNC only aliquots. In our hands, MGB1
transcripts were only detected in 9/35 (26%) of the single
tumor cells tested but because this marker is mammary-
specific, its inclusion in a panel of RT-PCR markers is war-
ranted. It is possible that the sensitivity with this marker
can be improved if more PCR cycles are performed.
ELF3, also known as Epithelial-Specific with serine bo X
(ESX), is a member of the Ets multigene family of tran-
scriptional regulators and is localised to chromosome
1q32 in a region known to be amplified in 50% of early
breast cancers [11,23].ELF3 mRNA expression is restricted
to tissues of epithelial origin, including normal and ma-
lignant human mammary ductal epithelium with no ex-
pression reported in lympho-haematopoietic tissues. In
our assay, faint bands were visible at 188 bp both after 45
cycles (1/6) and after 55 cycles (5/30) in the PBMNC only
aliquots. However the strong intensity of the bands for the
40/43 (93%) samples with a single tumor cell was consid-
ered indicative of a positive result in these cases. Decreas-
ing the cycle number to 35 eliminated the weak band in
the PBMNC only aliquots (0/15), yet still allowed consist-
ent detection of the tumor cells in our assay (15/16 –
94%) and therefore ELF3 is a useful marker for inclusion
in our panel.
EphB4 is a member of the Eph family of receptor protein
tyrosine kinases and has recently been reported to be up-
regulated in cancers from prostate, breast, endometrium,
lung and colon [12,24–27]. It is thought to play an impor-
tant role in the development and oncogenesis of various
tissues through modifications to cell-cell communication
and adhesion. Although EphB4 was detected in some PB-
MNC cell only controls at 55 cycles the level of intensity
of the corresponding bands on agarose gels was low and
decreasing the cycle number to 45 resulted in no positive
samples out of 21 tests. Using EphB4 specific primers with
45 cycles we could detect 77.5% of single tumor cells (31/
40) proving this to be an useful marker in this assay.
The various markers used here show different degrees of
heterogeneity i.e the numbers of single tumor cells that
they are detected in. Interestingly, the more heterogene-
ous markers also gave the least false positives in the con-
trols. It is unclear whether this is due to the sensitivity of
the test or due to stochastic differences in whether a cellBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/14
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expresses a transcript or not. Heterogeneity at the single
cell level must be taken into account when designing an
RT-PCR assay and this study is the first one to address this.
Using a panel of several markers will reduce this source of
error. This can be seen in table 3 where nearly every tu-
mour cell is positive for more than one marker. One T-
47D cell is negative for all 5 markers tested and it is possi-
ble that this cell was not viable at the time of selection.
The need to be both specific and sensitive may entail find-
ing a balance between the specificity and sensitivity. Our
findings in the PBMNC suggest that illegitimate transcrip-
tion occurs in all cells rather than a subset. When large
numbers of cells are present or the assay is very sensitive,
false positives will be common. ELF3 had a fairly high
false positive rate of amplification in PBMNC at 45 cycles
presumably due to detecting illegitimate transcription in
a very small number of these cells. However, ELF3 was one
of the more robust markers giving very strong amplifica-
tion of single tumour cells at 45 cycles. Amplification
from the controls was eliminated when only 35 cycles of
amplification were performed. Because only a small
amount of product was amplified after 45 cycles in these
controls we could distinguish samples that contained tu-
mor cells and those that did not through comparison of
the intensity of bands. This suggests that this and similar
markers will be useful in a real-time PCR methodology
where positive signals can be more readily differentiated
from background signals [15].
As mentioned, one question is whether cell lines are truly
representative of circulating tumor cells. A large number
of circulating tumor cells are believed to be in G0 [1],
whereas the cell line controls used are from log phase
cells. We compared the expression of ELF3, EphB4 and
EGFR in cells grown under conditions of serum starvation,
during log phase and at full confluence (data not shown).
We saw no appreciable difference in the expression levels
of any of these 3 genes under any of the conditions tested.
Whereas it is difficult to model the clinical situation,
where patterns of gene expression are likely to be hetero-
geneous, the assay presented in this communication is
useful for testing potential RT-PCR markers and as a
meaningful control in the determination of the presence
of disseminated tumor cells in clinical samples. To fully
validate these markers, a clinical study using immu-
nomagnetically enriched cells from patients is needed.
Such a study is currently in progress.
Conclusions
Immunobead RT-PCR is a powerful methodology for the
detection of disseminated carcinoma cells. We need RT-
PCR assays that are sensitive enough to detect very low
numbers of captured carcinoma cells As haematopoietic
cells may be non-specifically retained during immu-
nomagnetic enrichment of epithelial cells, these RT-PCR
markers also need to be tested for their specificity. A set of
RT-PCR markers has been tested for their ability to detect
a single carcinoma cell using a single round of PCR and
ethidium bromide visualization. We have identified six
useful markers that include the previously described
markers EpCAM,  EGFR, CEA and MGB1 as well as two
novel markers EphB4, and ELF3. This panel of markers
should allow the detection of virtually every tumor cell
and this means that a positive result will be obtained each
time an immunobead harvest has captured at least one
breast cancer cell. Most of these markers will also be useful
in the analysis of other carcinomas such as colon, lung
and prostate.
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